Eli Lilly's Tirzepatide shows reductions in blood sugar levels and weight

Drug candidate Tirzepatide for treating type II diabetes has shown significant reductions in average long-term blood glucose levels, A1C, and body weight, according to new Eli Lilly data.
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

New data from US pharmaceutical company Eli Lilly shows significant reduction in long-term blood sugar levels, A1C, and the body weights of patients when using the firm's drug candidate Tirzepatide's highest dose at 15 mg, according to an Eli Lilly press release on Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading